Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-04
DOI
10.1038/s41416-020-0912-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine
- (2019) May Levin et al. Cell Death & Disease
- Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
- (2019) Omidreza Firuzi et al. Cancers
- Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
- (2019) Michele Carbone et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies
- (2019) Btissame El Hassouni et al. SEMINARS IN CANCER BIOLOGY
- Characterization of glycolysis-related gene expression in malignant melanoma
- (2019) Andreas Koch et al. PATHOLOGY RESEARCH AND PRACTICE
- A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma
- (2018) Bryan M. Burt et al. Journal of Thoracic Oncology
- Concentrative Transport of Antifolates Mediated by the Proton-Coupled Folate Transporter (SLC46A1); Augmentation by a HEPES Buffer
- (2018) Rongbao Zhao et al. MOLECULAR PHARMACOLOGY
- Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma
- (2018) Paolo A. Zucali Journal of Thoracic Disease
- Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
- (2018) Kathrin Oehl et al. Frontiers in Oncology
- Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
- (2018) Rocco Sciarrillo et al. EBioMedicine
- Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
- (2017) Daniela Massihnia et al. Journal of Hematology & Oncology
- Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
- (2017) Andrea Cavazzoni et al. Oncotarget
- Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival
- (2017) Ilaria Pergolini et al. PLoS One
- Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
- (2016) Licun Wu et al. CLINICAL CANCER RESEARCH
- The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
- (2016) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Nuclear respiratory factor-1 (NRF-1) regulated hypoxia-inducible factor-1α (HIF-1α) under hypoxia in HEK293T
- (2016) Dan Wang et al. IUBMB LIFE
- Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma
- (2016) Yi Zhuo et al. MEDICINE
- A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1
- (2016) Elisa Giovannetti et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
- (2015) Nicole Degwert et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
- (2014) Leticia Leon et al. CURRENT DRUG TARGETS
- Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
- (2014) S Raz et al. Cell Death & Disease
- Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
- (2013) M Maftouh et al. BRITISH JOURNAL OF CANCER
- Lysine-5 Acetylation Negatively Regulates Lactate Dehydrogenase A and Is Decreased in Pancreatic Cancer
- (2013) Di Zhao et al. CANCER CELL
- Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter
- (2013) Christina Cherian et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
- (2013) A. Avan et al. CANCER RESEARCH
- Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor
- (2013) Emilia C. Calvaresi et al. CHEMBIOCHEM
- Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma
- (2013) Fabian Mairinger et al. Journal of Thoracic Oncology
- Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
- (2013) Daniel E. Schwed Lustgarten et al. Journal of Thoracic Oncology
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
- (2012) E. L. Servais et al. CLINICAL CANCER RESEARCH
- Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
- (2011) E Giovannetti et al. BRITISH JOURNAL OF CANCER
- Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
- (2011) P. A. Zucali et al. CLINICAL CANCER RESEARCH
- Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
- (2011) C M Goparaju et al. ONCOGENE
- The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
- (2011) D Barbone et al. Cell Death & Disease
- The Obligatory Intestinal Folate Transporter PCFT (SLC46A1) Is Regulated by Nuclear Respiratory Factor 1
- (2010) Nitzan Gonen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy
- (2010) Luisella Righi et al. JOURNAL OF CLINICAL ONCOLOGY
- PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells
- (2008) Nitzan Gonen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pleural fluid findings as prognostic factors for malignant pleural mesothelioma
- (2008) Tanseli Efeoglu Gonlugur et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial
- (2008) George R. Simon et al. JOURNAL OF CLINICAL ONCOLOGY
- The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier
- (2008) R. Zhao et al. MOLECULAR PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started